Guidelines and recommendations for ADHD in children and adolescents
CADTH
Record ID 32012000031
English
Authors' recommendations:
Evidence-based recommendations support the use of stimulants as first-line therapy and the consideration of symptom profile in the use of long- or short-acting formulations when treating children and adolescents with severe ADHD.
The drug payment information presented in this summary report reveals substantial use of health care budgets to reimburse long-acting formulations. In 2010, expenditures on long-acting medications had exceeded $35 million (or 77% of total expenditures on ADHD medications) by public drug plans in Canada.
Details
Project Status:
Completed
Year Published:
2011
URL for published report:
http://www.cadth.ca/media/pdf/RC0290_ADHD_Children_Adolescents_overview.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Attention Deficit Disorder with Hyperactivity
- Child
- Child, Preschool
- Adolescent
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.